Proposal number Study Sponsor(s) Title Lead researcher  
611GSKLong-acting beta2-agonists for chronic obstructive pulmonary diseaseKayleigh KewFurther Details
628GSKPredictive and Prognostic Value of Blood Cell Ratios in Patients with Metastatic Renal Cell Carcinoma Treated with PazopanibArnoud J. Templeton, MDFurther Details
631GSKPredictors of BPH ProgressionDr. Stephen Freedland, MDFurther Details
637GSKRelationship of Activated Clotting Time and Bleeding Related Outcomes in the FUTURA OASIS-8 TrialSripal BangaloreFurther Details
639GSKLow-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated With Fondaparinux in Patients with Peripheral Arterial DiseaseSaurav Chatterjee MDFurther Details
645GSKThe Influence of Age, Gender, and Race on the Effects of Combination Therapy with Carvedilol plus Lisinopril Versus Lisinopril Monotherapy for Systemic HypertensionPartha SardarFurther Details
646GSKFactors influencing immune response and patient outcomes following influenza vaccination.Dr Subhadra RajanaiduFurther Details
647GSKAssessing and Reporting Heterogeneity of Treatment Effect in Randomized Clinical TrialsDavid M. Kent, MD, MScFurther Details
651GSKDescriptive evaluation of SAE reporting rates in vaccine clinical trials among Latin American children.Thomas VerstraetenFurther Details
653GSKFunctional Estimation of Interventional EffectsJoon ParkFurther Details
654GSK, ViiVDevelopment of Population Pharmacokinetic/Pharmacodynamic Models for Pazopanib within the EuroTARGET project (Workpackage 7)Ulrich JaehdeFurther Details
657GSKUse of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trialsHolger Schunemann, MD, MSc, PhDFurther Details
668GSKAssociations between antihypertensive drugs and patterns of blood pressure changes: a strategy to reduce the burden of anti-VEGF induced hypertensionArduino A MangoniFurther Details
669GSKA multi-center, double-blind, placebo controlled study of paroxetine and imipramine in adolescents with unipolar major depression - efficacy and adverse outcomes.Jon JureidiniFurther Details
672GSKThe Development of Toxicity Prediction Tools to Assist Oncologists in the Management of Adverse Events in Patients Receiving Treatment with LapatinibDr. Mario LacoutureFurther Details
674GSKAntiepileptic drug monotherapy for epilepsy: an overview of systematic reviews and network meta-analysisAntony MarsonFurther Details
675NovartisValidation study on magnitude of tumorshrinkage as a prognostic markerViktor GrünwaldFurther Details
679GSKAn Epigenetic Analysis of the ALOX5 Gene Related to the Clinical Response to MontelukastWayne H AndersonFurther Details
681GSKA randomized, double blind, placebo-controlled trial to evaluate the effect of rosiglitazone on metabolic markers in psoriasis patientsAlexa B. KimballFurther Details
911GSKOutcome Measures in Systemic Lupus Erythematosus: Constructing a Meaningful Response Index from Existing Clinical Trial DataLindsy Forbess, MD, MScFurther Details
918GSKOutcomes after Percutaneous Coronary Intervention in Cancer patients with Acute Coronary SyndromePartha Sardar MDFurther Details
928GSKLung function and airway inflammation response after ozone exposure 0.25ppmKrista Todoric, MDFurther Details
930GSKMASTERMIND: Stratification of glycaemic response the ADOPT and RECORD studiesProfessor Andrew Hattersley, M.D. FRSFurther Details
946GSK, RocheAssessing models for changes in tumour size over time and how they relate to survival times.Raluca EftimieFurther Details
951GSKOptimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopeniaMohammad SalehFurther Details
955GSKA study of subgroup identification and micro aggregationS. Stanley YoungFurther Details
956RocheBone Quality ProjectDennis M. BlackFurther Details
976GSK5-alpha reductase inhibitor use and risk of lung cancerMarshall PitzFurther Details
977GSKThe implication of central adjudication of COPD exacerbations by experts for treatment effect estimates and sample size calculationMilo PuhanFurther Details
980GSKAssociation of leukotriene C4 synthase gene (rs730012, -444 A/C) polymorphism with response to leukotriene modifiers treatment in asthma patientsYi-Fan WuFurther Details
982ViiVPharmacokinetic modeling of dolutegravir in HIV patients.V P Subramanyam RallabandiFurther Details
988RochePhD Project: Bayesian Multivariate Network Meta-Analysis of Ordered Categorical DataFabrizio MessinaFurther Details
989GSKAssessing at the participant level the applicability of clinical trials to a specific patientAmos CahanFurther Details
993GSKA Spirometric Z-Score Based Reappraisal of the TORCH Study(GSK-SCO30003): Salmeterol and Fluticasone Propionate in COPD.Carlos A. Vaz Fragoso, MDFurther Details
995Boehringer Ingelheim, GSK, Lilly, Roche, Takeda, UCBIdentifying immune modulating patterns across diseases from open clinical trial dataFurther Details
997GSKPredictors of Prostate Cancer Progression Among Men on Active SurveillanceStephen Freedland, MDFurther Details
998GSKDetermination of minimally important difference for short form 36 and Facit Fatigue for Systemic lupus erythematosusMeenakshi Jolly, MD, MSCPFurther Details
999Boehringer Ingelheim, GSKAssessing the Comparative Efficacy of Therapeutics for Chronic Obstructive Pulmonary Disease (COPD): A Meta-Analysis of Randomized TrialsKristen M SweetFurther Details
1000GSKReview of fever and febrile convulsion rates in children after trivalent influenza vaccine.Dr Jean Li-Kim-Moy, MBBS, FRACPFurther Details
1002GSKLong-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary diseaseMichael SaraiFurther Details
1013GSKBiopsy Avoidance in Patients At Risk For Prostate Cancer and in Patients With Low Risk Prostate Cancer: Developing Tools for Personalized MedicineGirish Kilkarni, MD, PhDFurther Details
1015GSKPazopanib induced liver toxicity: incidence, pathogenesis and value of liver enzymes increase as a predictor of outcome in metastatic soft tissues sarcoma patients. A retrospective multi-centric studyBruno Vincenzi, MD, PhDFurther Details
1016GSKStatistical methods for estimating the duration of protection of malaria vaccines: secondary analysis of data from the RTSS/AS02A trial in Mozambique.Paul MilliganFurther Details
1020GSKGenomic prediction tools developed using phenotypes from disease progression modelsManish Sharma, MDFurther Details
1022NovartisPrediction of maximal work load (Wmax)in a bicycle test in patients with COPD.Göran ErikssonFurther Details
1028ViiVImpact of dolutegravir on CD4+/CD8+ ratio and CD4+ percentage in HIV-infected naive patients.José Ramón BlancoFurther Details
1053GSKValidation of the spirometric LMS equations in the Spanish populationDr. Patricia SobradilloFurther Details
1057GSKHealth-related utility and disutility value in metastatic renal cell carcinoma patient treated with pazopanibChang Wook JeongFurther Details
1058ViiVRitonavir-boosted protease inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimens: a systematic review and individual patient data meAlvaro H BorgesFurther Details
1071Boehringer Ingelheim, GSKOptimising the Analysis of vascular Prevention trials (OA-Prevention)Further Details
1073GSKEnd-of-life trajectories in COPDDr. Daisy J.A. JanssenFurther Details
1075RocheEfficacy and Safety of Bevacizumab in the Elderly Cancer Patients: Pooled Analysis of Ten Randomized Clinical TrialsXiaofei WangFurther Details
1078LillyNocebo effects in the treatment of bipolar disorder: Results from an individual study participant level meta-analysis of the placebo arm of olanzapine clinical trialsSeetal DoddFurther Details
1079ViiVThe effects of maraviroc versus efavirenz in combination with zidovudine/abacavir on the CD4/CD8 ratio in treatment-naïve HIV-infected individuals.Sergio Serrano-Villar, MD PhDFurther Details
1084GSKStudies on the relationship between corticosteroids and unfavorable medical effects. A study based on the BLISS-52 and BLISS-76 clinical trials.Ronald van Vollenhoven, MD, PhDFurther Details
1085RocheOptimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis BMohammad I Saleh, PhDFurther Details
1086ViiVAbacavir HLA-B*57:01 tolerance and genetic variation within the MHC.Elizabeth Phillips, MDFurther Details
1088GSKA study to identify risk factors that modify Rotarix efficacy and influence the time to rotavirus gastroenteritis among vaccinated and unvaccinated African infants.Joann GruberFurther Details
1090GSKValidating the test-negative case-control design for estimating rotavirus vaccine effectiveness using gold-standard randomized controlled trial data from South Africa and Malawi (Rota-037)M. Elizabeth HalloranFurther Details
1100Boehringer IngelheimSystolic blood pressure level and risk of intracerebral hemorrhage.Jacoba P GrevingFurther Details
1103GSKA study on the possible association between antidepressant response to SSRIs and proneness for side effectsElias Eriksson, MD, PhDFurther Details
1108GSKCorrelation between SF-36 PCS and MCS scores and SELENA SLEDAI activity score in SLE: a meta-anaysis.Chaigne BenjaminFurther Details
1125LillyInitial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies.Stefan LeuchtFurther Details
1128GSKEuroTARGET GWAS on sunitinib pharmacogenetics in patients with metastatic renal cell carcinomaProf. H.J. GuchelaarFurther Details
1130GSK, UCBFactors that determine placebo response in epilepsy trialsEmilia BagiellaFurther Details
1132GSKCytokine patterns in anti-viral disease vaccines: a knowledge driven approachAtul J. Butte, MD, PhDFurther Details
1134GSKIncidence rate and risk factors associated with Hepatocellular carcinoma development in patients with Chronic Hpatitis C and severe thrombocytopenia: the lesson from Enable studiesProf. Savino Bruno, MDFurther Details
1136TakedaCan Machine Learning Algorithms using General Labs Predict Clinical Remission and Mucosal Healing for Patients on Vedolizumab?Peter HigginsFurther Details
1137GSKImmunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease.Roy Anderson, PhDFurther Details
1140Boehringer IngelheimEvaluation of the effect of incidental beta blocker use on clinical response to the EGFR TKI, afatinibJohn Heymach, MD, PhDFurther Details
1141GSKMultivariate methods for meta-analysis of vaccine studies with multiple correlated outcomesMerryn VoyseyFurther Details
1142Boehringer Ingelheim, GSK, UCBA meta-analysis of Parkinson’s diseaseAtul ButteFurther Details
1148LillyMeta-analysis of the risk of relapse in bipolar disorderDr. Joaquim RaduaFurther Details
1152Boehringer IngelheimAdvanced analytic methods to refine phenotyping and risk prediction among patients with atrial fibrillation in the RE-LY trialNihar Desai, MD, MPHFurther Details
1154GSKDeveloping New Outcome Measures for SLE by Deconvoluting Available DatasetsPeter E. Lipsky, MDFurther Details
1157GSKQuality-adjusted survival analysis for patients with metastatic renal cell carcinoma treated in a phase III trial of pazopanib versus sunitinib (COMPARZ trial)Chang Wook JeongFurther Details
1159ViiVValidation of Pharmacokinetic/Viral Dynamic Modeling and Simulation using the Dolutegravir Phase IIa DatasetEdward P. Acosta, Pharm.D.Further Details
1160Boehringer IngelheimDevelopment of a clinical decision support tool to identify patients at high risk of early or late bleeding complications from anticoagulationMark H. Ebell MD, MSFurther Details
1161RocheNovel approaches to the prediction of influenza complicationsMark H. EbellFurther Details
1173GSK, LillyInitial severity and antidepressant efficacy for anxiety disorders: an individual patient data meta-analysisYmkje Anna de VriesFurther Details
1180GSKEvaluation of a platelet count threshold for bleeding risk in thrombocytopenic patients with chronic liver disease who undergo diagnostic and therapeutic invasive procedures.Edoardo G. GianniniFurther Details
1186GSKUsing generalized pairwise comparisons to assess the benefit/risk balance of pazopanib vs sunitinib for patients with advanced or metastatic renal cell carcinomaMarc BuyseFurther Details
1206GSKEfficacy of Belimumab on Mucocutaneous Involvement in Patients with Systemic Lupus Erythematosus (MUCOBEL)Kuhn, AnnegretFurther Details
1234LillyPredictors of Placebo Response in Pediatric Patients with Generalized Anxiety DisorderJeffrey R. StrawnFurther Details
1236GSKCOPERNICUS re-analysisJohn ClelandFurther Details
1250Boehringer Ingelheim, LillyThe relationship of treatment effects and per capita income of study countries in duloxetine trials in the treatment of depressed patientsMarkus KoestersFurther Details
1256GSKPopulation mechanistic heamatotoxicity modeling of Dapsone in G6PD deficiency patientsJoel TarningFurther Details
1257GSKAn independent evaluation of the cardiovascular risk of rosiglitazone: meta-analysis of GSK’s publicly available clinical trial dataJoseph S. Ross, MD, MHSFurther Details
1258RocheAdvance lung cancer inflammation index (ALI) in metastatic non-squamous lung cancer: A validation studySyed Hasan Raza JafriFurther Details
1273GSKPost-hoc analysis of placebo-controlled trials in children and adolescents with depressionElias ErikssonFurther Details
1277RocheImmunotherapy trial simulators: Using mathematical, computational and statistical techniques to simulate trial design for new products in the treatment, vaccination and immunoprophylaxis of disease.Roy AndersonFurther Details
1280GSKPlacebo and nocebo effects in migraine Ver 2Paul EnckFurther Details
1292LillyApplications of Item Response Theory to Clinical ADHD Research: Analysis of the ADHDRS-IV and Modeling Response to Treatments and Item-Level Treatment SensitivityAlex SturmFurther Details
1295Boehringer Ingelheim, GSKA Swapping Method Based on Covariate Classification for Average Treatment Effect Estimation.Dr. Bimal SinhaFurther Details
1307TakedaThe Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney DiseaseDr. Navdeep TangriFurther Details
1316Boehringer IngelheimBlinding (Masking) and the Placebo EffectJames Brian Byrd, MD, MS, FAHA, FACCFurther Details
1320GSKUtility of a measure of Lupus Low Disease Activity State in SLEPei Xuan Ong (Emily)Further Details
1321GSKBone Quality ProjectDennis M. BlackFurther Details
1322GSKComparative efficacy of different therapeutic approaches in the "naïve" patient with chronic obstructive pulmonary disease (COPD): analysis of patient-level dataGiulio ParetoFurther Details
1323LillyDetection of uninformative clinics during the trial of a new drug using statistical and machine learning techniquesPraveen DeoraniFurther Details
1326LillyReliability and Validity of the Parent Rating of Evening and Morning Behavior Scale, RevisedSteven V. Faraone, Ph.D.Further Details
1331Boehringer IngelheimImpact of baseline diabetes and obesity statuses on outcomes post-ischemic strokeColleen BauzaFurther Details
1335GSK, UCBInvestigation into the natural course of epilepsy and the implications on clinical trialsDaniel GoldenholzFurther Details
1341Boehringer IngelheimVol-PACT: Improving Volumetric CT Metrics for Precision Analysis of Clinical Trial ResultsGeoffrey R. OxnardFurther Details
1343GSKImproving the Assessment of Systemic Lupus Erythematosus Disease ActivityZahi ToumaFurther Details
1373GSKAn exploratory analysis of headache in placebo controlled trials of paroxetine for generalized anxiety disorderJonathan H. Smith, M.D.Further Details
1374GSKA novel representation of vaccine efficacy trial datasets for use in computer simulation of vaccination policyMichael M. WagnerFurther Details
1377GSKThe association between patient outcomes under two treatments (ABOUT) in cross-over trialsMarc Buyse, ScDFurther Details
1387GSKSex-differences in immunogenicity, reactogenicity and efficacy in response to vaccines in infants and young childrenMerryn VoyseyFurther Details
1393RochePrognostic influence of body mass index and body weight gain in colorectal cancer patients treated with adjuvant chemotherapy: data from The AVANT studySae-Won HanFurther Details
1401SanofiUse of Heparins in patients with Cancer: Individual patient-data meta-analysis of randomized trialsHolger SchunemannFurther Details
1403ViiVMathematical modeling of the HIV transmission risk during the first 24 weeks after initiation of antiretroviral therapy in naïve HIV-infected MSMJuan BerenguerFurther Details
1421GSKCost utility analysis comparing belimumab against rituximab in systemic lupus erythematosusChris GilletteFurther Details
1422UCBDeveloping new outcome measures for SLE by deconvoluting available data setsPeter E. Lipsky, MDFurther Details
1428Boehringer IngelheimEstimating absolute treatment effect of dabigatran 110 mg bid vs. 150 mg bid (vs. warfarin) for individual patients with atrial fibrillation.Frank L.J. VisserenFurther Details
1430GSKComparison of various remission criteria for SLE. A study based on the BLISS-52 and BLISS-76 clinical trials.Ronald van VollenhovenFurther Details
1433Boehringer Ingelheim, Lilly, RocheIdentification of patient subgroups with enhanced treatment response in RCTs with time-to-event outcomes: use of counterfactual restricted survival times.Ludovic TrinquartFurther Details
1450Boehringer Ingelheim, NovartisUnderstanding effectiveness of new drugs in older adults shortly after market entry.Shirley V WangFurther Details
1451GSKAssessment of bias from treatment discontinuation on mortality and exacerbations in the Towards a Revolution in COPD Health (TORCH) randomized trialSamy SuissaFurther Details
1452GSKA study to determine if prior rotavirus exposure modifies the effect of rotavirus vaccines given to infants in low- and middle-income African countriesSylvia Becker-DrepsFurther Details
1455Boehringer IngelheimPrediction of major bleeding in atrial fibrillation patients with a history of stroke or transient ischemic attackJacoba GrevingFurther Details
1456ViiVImpact of ongoing side effects on the efficacy of initial antiretroviral therapyAndrew CarrFurther Details
1457LillyInitial severity and efficacy of antipsychotics for schizophrenia and bipolar mania: Individual participant level analyses of placebo-controlled studies.Stefan LeuchtFurther Details
1461LillyRegression discontinuity designs to evaluate real-world clinical effectiveness: a case study of drotrecogin alphaAllan J. WalkeyFurther Details
1470Takeda, UCBThe efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel diseaseShomron Ben-Horin M.D.Further Details
1473RocheComparison of the pharmacokinetics of oral once-monthly 150mg ibandronate between ethnic Europeans and Taiwan post-menopausal osteoporotic women across two phase 1 studiesKeh-Sung TsaiFurther Details
1475Boehringer IngelheimPredicting safety and efficacy of afatinib treatment of NSCLCAssoc/Prof Michael SorichFurther Details
1481GSKEfficacy and safety of belimumab in childhood-onset lupusDr Anca Askanase MD, MPHFurther Details
1514RocheGain of quality-adjusted life year in patients with neovascular age-related macular degeneration after anti-VEGF treatmentPark, Sang JunFurther Details
1526GSKAssessment of correlations among all favourable and unfavourable effects for rosiglitazone/metformin, and for metformin alone, in Type 2 diabetes.Lawrence D PhillipsFurther Details
1528GSK, Lilly, RocheA Swapping Method for Average Treatment Effect EstimationBimal SinhaFurther Details
1540GSKIMPROVING METHODS. Our research focus is to optimize the translation of clinical trial results into clinical practice.Dr. Issa DahabrehFurther Details
1541RocheItem calibration of the NEI VFQ-25 to improve future comparative research using patient-reported outcome (PRO) measures.Judith E. GoldsteinFurther Details
1542Boehringer IngelheimOptimising the Analysis of vascular Prevention trials (OA-Prevention)Philip BathFurther Details
1558GSK, NovartisDevelopment of historical control using placebo data from pediatric epilepsy studiesAnthony DanielsFurther Details
1566LillyA microanalysis of symptoms and behaviors defining ADHD in adults and their response to both active medication and placeboFrederick W. Reimherr MDFurther Details
1567Boehringer Ingelheim, TakedaStratification of SGLT2 inhibitor glucose lowering therapy in Type 2 diabetesAndrew HattersleyFurther Details
1569GSKMelancholic symptoms in bipolar depression and response to lamotrigineDr. Evyn PetersFurther Details
1572Boehringer Ingelheim, Eisai, GSK, LillyResearch to evaluate the relation of toxicity and the relative dose intensity in phase I trials beyond cycle 1 of Molecular Targeted Agents (MTAs)Kan Yonemori, MD., PhDFurther Details
1575GSK, LillyEarly improvement in individual symptoms and response to antidepressants in patients with major depressive disorderYmkje Anna de VriesFurther Details
1581GSKMASTERMIND: Assessing the cost effectiveness of a stratified approach to type 2 diabetes therapyProfessor Chris JennisonFurther Details
1587AstellasSex-specific efficacy of mirabegron for overactive bladder (OAB) symptoms: individual patient data meta-analysesMarco H. Blanker, MD PhDFurther Details
1593GSKJANUVIA/JANUMET HTA Submission(Germany)Dr. Rainer WokerFurther Details
1595Boehringer Ingelheim, GSK, Lilly, RocheA Novel Approach to Developing Comprehensive Profile of Adverse Event (AE) Data from Clinical TrialsSharayu ParanjpeFurther Details
1599RochePredictors of exposure, adverse and therapeutic effects of BRAF/MEK inhibitors in advanced melanoma.Michael SorichFurther Details
1600LillyItem factor analysis of the SNAP-IV Parent Report Form: Generating item parameter estimatesAlexandra Sturm, Ph.D.Further Details
1601SanofiIdentification of clinical biomarkers for adjuvant chemotherapy for gastric cancer after D2 dissection by analyses of individual patents’ data from large randomized controlled trialsAkira Tsuburaya, MD PhDFurther Details
1619Boehringer IngelheimThrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke: reanalysis of ECASS III trial to assess robustness of findings across statistical modelsBrian S. Alper, MD, MSPH, FAAFPFurther Details
1622ViiVA systematic literature review and Individual patient-level data enhanced network meta-analysis to determine the comparative efficacy and safety of first-line HIV antiretroviral therapiesSteve KantersFurther Details
1624LillyA Meta-analysis of Tardive Dyskinesia Rates in Studies Comparing Second Generation Antipsychotics (SGAs) with each other or to First-Generation Antipsychotics (FGAs).Christoph U CorrellFurther Details
1626GSKFactors associated with Prostate Cancer in Prostate Needle BiopsyDaniel M. MoreiraFurther Details
1629GSKAssessing sex-differences and the effect of timing of vaccination on immunogenicity, reactogenicity and efficacy of vaccines in young childrenMerryn VoyseyFurther Details
1630GSKA framework for individualized prediction of the rate and severity of asthma exacerbationsMohsen SadatsafaviFurther Details
1633ViiVComparative effect of dolutegravir and raltegravir on CD4+/CD8+ ratio, CD4%, and multiple T-cell marker recovery. SPRING-2 study.Jose Ramon BlancoFurther Details
1637Novartis1618 - Optimizing Patient Reported Outcomes by Linking Study Endpoints to Real-World BenchmarksDr. Jeffrey LacknerFurther Details
1640GSKEffect of Fluticasone/Salmeterol on Chronic Bronchitis Symptoms and Associated Patient Reported Outcomes: a post-hoc analysis of the TORCH trialVictor KimFurther Details
1643Astellas, Lilly, Novartis, RocheDevelopment of an accurate statistical method for evaluating region-specific treatment effects in multiregional clinical trialsHisashi NomaFurther Details
1646LillyEffects of tumor burden change (response) on survival in mesotheliomaAaron MansfieldFurther Details
1654GSK, LillyPlacebo Response in Major Depressive Disorder.Ariana AndersonFurther Details
1660SanofiAssessing the generalizability of all-cause mortality from the MOSAIC trial to older adults diagnosed with stage II and III colon cancer in SEER-MedicareJennifer L. LundFurther Details
1668RocheQuantitative Evaluation of Circadian Rhythm of Serum Glucose Level in Caucasian and Chinese Type 2 Diabetic Patients (Oct/2016)Pei HuFurther Details
1675LillyEfficacy and tolerability of SNRIs in depression.Elias ErikssonFurther Details
1684RocheANSELMA Antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy: an individual patient data meta-analysisBENJAMIN BESSEFurther Details
1688NovartisTranslational data from LPT109096 to assess the impact of HER2-targeted therapies on HER-family and stem cell marker expression.Denis CollinsFurther Details
1691GSKLongitudinal Concurrent and Predictive Biomarkers of Clinical Disease Severity in Systemic Lupus Erythematosus in BLISS-52/BLISS-76Austin HuangFurther Details
1692Boehringer Ingelheim, GSKPredictors of chronic obstructive pulmonary disease progressionAkihiro HisakaFurther Details
1693Lilly, NovartisIdentifying Subgroups of Response to Biologics in Psoriasis using Large-scale Patient-level DataNophar GeifmanFurther Details
1695GSKOutcome measures and baseline predictors of response to belimumab treatment.Ioannis ParodisFurther Details
1702RochePooled analysis of cardiac safety of T-DM1 in HER2-positive metastatic breast cancer patientsEvandro de AzambujaFurther Details
1707LillyComparative Effectiveness Analysis with Data From Randomized Clinical Trials and Observational StudiesHerbert PangFurther Details
1721Lilly, RocheImproving the evaluation of new cancer therapies to expedite patient accessProfessor Jonathan KarnonFurther Details
1726Takeda, UCBAssociation Between Obesity and Response to Biologic Therapy in Inflammatory Bowel DiseasesSiddharth SinghFurther Details
1731GSKHost characteristics impacting Rotarix immunogenicity and correlates of protection for rotavirus gastroenteritis, a multi-site pooled analysis of individual-level clinical trial dataJulia M. BakerFurther Details
1732Astellas, Boehringer Ingelheim, Daiichi Sankyo, GSK, Lilly, Novartis, Roche, Sanofi, Takeda, UCBAssessing heterogeneity in relative treatment efficacy by age, sex and comorbidity.Dr David A McAllisterFurther Details
1733RocheIdentifying Trajectories of Disease Activity States in Juvenile Idiopathic Arthritis (JIA) Early After Treatment: Shortening Time to Decision to Change TreatmentLily LimFurther Details
1741Lilly, Novartis, RochePredictors of exposure, therapeutic and adverse effects of drugs used in the treatment of advanced breast cancer and advanced colorectal cancer.Dr Ashley Mark HopkinsFurther Details
1749GSK, Novartis, RocheBisphosphonates for the Treatment of Osteoporosis In Chronic Kidney Disease: an Individual Patient Level Systematic Review and Meta-AnalysesDr. David CollisterFurther Details
1752GSKSex Differences in responses to umeclidinium-vilanterol treatment in COPD patientsElisabetta StrafaceFurther Details
1758NovartisChange in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney DiseaseLesley A. Inker, MDFurther Details
1764Sanofi, TakedaPersonalized Medicine Model Builder and Evaluation for Diabetes TreatmentsAdam KapelnerFurther Details
1779GSKEvaluation of the effect of inhaled corticosteroids (ICS) on blood eosinophil count (EOS) in patients with COPDProfessor Jørgen Vestbo DMSc FRCP FERSFurther Details
1786Lilly, Novartis, UCBThe efficacy of biologic medications in improving depressive symptoms in patients with psoriasis and PsA – Patient-level meta-analysis of randomized clinical trials dataDr Lihi EderFurther Details
1794RocheA study to identify the associated factor of reported adverse event severity among HER2-positive metastatic breast cancer patient from clinical trials.OH CHEN WEIFurther Details
1808Roche, UCBLong-term predictive value of patient global assessment regarding radiographic damage and physical function in patients with Rheumatoid Arthritis: individual patient data meta-analysisJosé A. P. da SilvaFurther Details
1813Takeda, UCBComparative efficacy of biologics in resolving extraintestinal manifestations of inflammatory bowel disease (IBD): a systematic review and meta-analysisPurna C. Kashyap, MBBSFurther Details
1816Lilly, RocheIndividual patients data based meta-analysis of randomized trials assessing the interest of molecularly targeted treatments of advanced/recurrent stomach cancer: A meta-analysis by the GASTRIC groupXavier PaolettiFurther Details
1831GSK, Novartis, TakedaStatistical Methods Research to Compare the Performance of New Estimators of the Treatment Effect in Alzheimer’s Disease Randomized TrialsMichael RosenblumFurther Details
1843GSKThe genetics of glycaemic response to GLP-1 receptor agonists in Type 2 diabetesEwan PearsonFurther Details
1844GSKReal World Effects of Medications for Chronic Obstructive Pulmonary DiseaseDr Kevin WingFurther Details
1847SanofiAntiangiogenic Second line Lung cancer Meta-Analysis (ANSELMA) - A meta-analysis on antiangiogenic agents in advanced non-small cell lung cancer patients who failed first-line chemotherapy.Benjamin BesseFurther Details
1851RocheValidation of a Novel Outcome Instrument for SLE Clinical Trials Using Phase II Rontalizumab Study Data Set.Kenneth KalunianFurther Details
1857GSK, NovartisComparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysisAndrea C. TriccoFurther Details
1880Boehringer Ingelheim, Eisai, Lilly, Roche, SanofiImproving the evaluation of new cancer therapies to expedite patient accessProfessor Jonathan KarnonFurther Details
1907GSKCritical characterization of the impact of clinical-pathological tumoral features on recurrence risk dynamics of NSCLS.Tommaso De PasFurther Details
1911Boehringer Ingelheim, Daiichi SankyoLower incidence of atrial fibrillation in NOAC treated patients without prior AFÖmer ErkünerFurther Details
1925GSKEstablishINg the best STEp-up treatments for children with uncontrolled asthma despite Inhaled corticosteroids (EINSTEIN): A systematic review, network meta-analysis and cost effectiveness analysisCatrin Tudur SmithFurther Details
1928GSKThe development of a disease progression model to describe the long-term effects of anti-diabetic medications on Hemoglobin A1CMohammad SalehFurther Details
1933NovartisBenefit-harm assessment of Fingolimod: a novel methodology to inform patients with MS, industry, guideline developers and regulatory agencies on the balance of benefits and harmsAlessandra SpanuFurther Details
1934GSKUsing zanamivir trial data to evaluate baseline characteristics and disease progression by various subgroups to inform clinical development of novel therapies in hospitalized patients with influenzaLesley ButlerFurther Details
1955Boehringer IngelheimDevelopment and validation of a model to predict absolute vascular risk reduction due to intensive blood-pressure targets in individual patients at baseline and after three monthsF.L.J. VisserenFurther Details
1996SanofiStatistical Methods for Causal Inference Adjusting for AdherenceDaniel HeitjanFurther Details
2033Applying machine learning tools to personalize dabigatran treatment decisionsSanjay BasuFurther Details
2036Boehringer IngelheimPrediction of bleeding events in patients with non-valvular atrial fibrillation - validation of the VTE-BLEED scoreMenno V HuismanFurther Details
2056LillyBreakthrough on Antipsychotic Maintenance Medication: An Individual Participant Data Meta-Analysis.Jose M Rubio M.D.Further Details
2069LillyEstimating the impact of different approaches to the analysis of time-to-event and longitudinal data on modelled cost-effectiveness.Ben KearnsFurther Details
2074RocheAssociation between pertuzumab induced diarrhea and cutaneous rash and survival outcomes in patients with HER2-positive metastatic breast cancer enrolled in the CLEOPATRA trialEvandro de AzambujaFurther Details
2084GSKRelationship between plasma levels of a1-Antitrypsin levels and the severity of airflow limitationMarc MiravitllesFurther Details
2085GSKIdentify Systemic Lupus Erythematosus (SLE) Patients Treated with Belimumab with Reduced Severe and Severe/Moderate Flares: A Post-hoc Trial AnalysisHongjun KanFurther Details
2087LillyEffectiveness of rhGH in Children with GHD in GeNeSIS (NCT01088412) - revisedMichael O. ThornerFurther Details
2099Boehringer IngelheimBlood pressure variability in PRoFESS and development of incident strokeAdam de HavenonFurther Details
2100GSKReview of post-vaccination fever and antipyretic use and their relation to vaccine immunogenicity after quadrivalent influenza vaccine in children.Dr Jean Li-Kim-MoyFurther Details
2110LillyEffects of tumor burden change (response) on survival in mesotheliomaAaron MansfieldFurther Details
5453RocheEvaluation of Postmastectomy Radiotherapy in Women with HER-2 positive Breast CancerYoussef ZeidanFurther Details
5459GSKPlacebo Effects in Asthma Randomized Clinical Trials: Their Magnitudes, Causes and Potential for Improving CareShawn D. AaronFurther Details
5460GSKThe evaluation of hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection against laboratory-confirmed influenza infectionsProf Benjamin J CowlingFurther Details
5471GSK, LillyEvaluating predictors of antidepressant response or remission in children and adolescents with depressionO'Mareen Spence, MPHFurther Details
5494SanofiImproving Colon Cancer Therapy Decisions by Extending Trial RepresentationJennifer LundFurther Details
5495Applying clinical trial results in clinical decision-making: Impact of a patient’s baseline risk on the relative effect of an intervention strategy.Frank L.J. VisserenFurther Details
5499RocheIncorporating biomarkers into survival models to predict patientDr. Luigi Brunetti, PharmD, MPHFurther Details
5501RocheEfficacy and Tolerability of Trastuzumab-Emtansine in Elderly Patients with Advanced Breast Cancer – A Combined Analysis Noam PondéFurther Details
5502LillyHealth Determinants of the quality of life among children with ADHD: a structural equation modelling approachNadia MinicuciFurther Details
5504Estimating Oral Anticoagulant Comparative Effectiveness in the Setting of Effect Heterogeneity: Comparing Clinical Trial Transport and Observational Epidemiologic MethodsMichael Webster-ClarkFurther Details
5505Boehringer Ingelheim, LillyA Data-Driven Statistical/Machine Learning Analysis for Extracting Clinically Actionable Predictions of Antidepressant Treatment Outcomes with Individual Depressive SymptomsWilliam V. BoboFurther Details
5506LillyDevelopment of a limited sampling strategy for pharmacokinetic studies with pemetrexed.Rob ter HeineFurther Details
5509Boehringer IngelheimStatistical methodology for the analysis of incomplete data in non-inferiority clinical trials.Yulia SidiFurther Details
5513Lilly, NovartisAssociation of sunlight intensity with Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms and interactions with pharmacological treatment: A cross-sectional approach.Martijn ArnsFurther Details
5515GSKImpact of HPV16/18 vaccine on HPV genotype infection and cervical precancerous lesions: an implication for cervical cancer screening strategyFanghui ZhaoFurther Details
5521GSKImpact of HPV vaccination in preventing subsequent infection and disease after excision treatmentFanghui ZhaoFurther Details
5525GSKNovel approaches for the analysis of SLE clinical trialsMimi KimFurther Details
5528Boehringer IngelheimSpirometric Z-Score Reappraisal of the UPLIFT Trial: A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseCarlos A. Vaz Fragoso, MDFurther Details
5548Boehringer Ingelheim, Lilly, RochePredictors of exposure, therapeutic and adverse effects of targeted therapeutics used in the treatment of lung cancer.Ashley HopkinsFurther Details
5565EisaiPredictors of exposure, therapeutic and adverse effects of lenvatinib used in the treatment of advanced thyroid cancer.Ashley HopkinsFurther Details
5567LillyPROCLAIM trial secondary analysis: Request for data to determine pre- and mid-treatment neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios and lymphocyte nadir values to analyze if they are predictive of survival outcome.Tithi BiswasFurther Details
5602RochePredictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers.Ashley HopkinsFurther Details
5625RocheInvestigating the effects of rituximab on specific cell subsets and cytokine levels in systemic lupus erythematosus patients and constructing a prediction model of treatment responseMatthew BakerFurther Details
5652UCBEfficacy of Crohn’s Disease Treatment Stratified by Disease PhenotypeVivek RudrapatnaFurther Details
5658GSKDoes Shingrix vaccination reduces the risk of stroke? Benson OgunjimiFurther Details
5742Boehringer Ingelheim, GSK, NovartisComparison of the effects of dual and single bronchodilators in COPD patients relocated from group D to group B by the revised 2017 GOLD classification: a post-hoc pooled analysis of global RCTsYeon-Mok OhFurther Details
5806GSKMelancholic depression and response to lamotrigine for the treatment of acute bipolar depression: a pooled analysis of five randomized controlled trialsDr. Evyn PetersFurther Details
5808RocheEffect of rheumatoid factor and anticitrullinated peptide antibody on the efficacy of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisDiane van der WoudeFurther Details
5809RocheEffectiveness of anti HER2 blockade according to host immune statusJoon JeongFurther Details
5815GSKExamining statistical methods to allow comprehensive evaluation and presentation of adverse event data in randomised controlled trialsRachel PhillipsFurther Details
5835GSKCombined effect of belimumab and hydroxychloroquine treatment : results from the phase 3 belimumab clinical trials in patients with SLESavino SciasciaFurther Details
5855GSKA clinical practice for detecting the phases of Herpes Zoster.Dimitris KarlisFurther Details
5862GSKImpact of belimumab on antiphospholipid antibodies in patients with Systemic Lupus ErythematosusKaterina ChatzidionysiouFurther Details